The significance of extension and impaired mobility in cancer of the vocal cord

Journal Article · Tue Feb 01 00:00:00 EST 1983 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

DOI:https://doi.org/10.1016/0360-3016(83)90096-2· OSTI ID:5587134

Van Den Bogart, W; Ostyn, F; Van Der Schueren, E

The criteria for T2 glottic cancer staging in the UICC classification are extension to the supra- or subglottic region combined or not with impaired mobility of the vocal cord. The prognostic significance of these factors is examined in this study. Patients with T2A lesions (normal mobility, 33 patients) have an uncorrected actuarial 5 year survival of 54%, and a local control rate with radiotherapy alone of 62%. Patients with T2B lesions (impaired mobility, 28 patients) have a survival of 40% and a local control rate of 65% with radiation only. After rescue surgery, local control is obtained in 81% of T2A patients and 68% of T2B patients. While local control rates with radiotherapy alone were the same in T2A and T2B patients, final survival was lower for T2B patients because of less successful salvage surgery. While no significant differences in local control were found for different mucosal spread patterns, local control was excellent (87%) with radiotherapy alone in eight patients with mobility impairment without extension beyond the true cord, indicating that impaired mobility by itself is not a bad prognostic factor, but only when it is combined with tumor extension. In 9 patients with T2B tumors, a laryngectomy was performed immediately after initial radiotherapy (40 or 50 Gy) when the tumor persisted or the vocal cord mobility did not return to normal. None of these patients had a local recurrence after surgery. The total local control in all 37 T2B patients together was 78% (compared with 81% in T2A patients). The adverse prognostic influence of impaired mobility seems to have been eliminated by the treatment policy of surgery for those patients with poor regressions after radiotherapy. A dose-response relation can not be demonstrated in T2 glottic cancer for the dose range between 50 and 70 Gy.

• Research Organization: Univ. of Leuven, Belgium
• OSTI ID: 5587134
• Journal Information: Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 9:2
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
RADIOTHERAPY
EVALUATION
COBALT 60
DOSE-RESPONSE RELATIONSHIPS
GAMMA RADIATION
NECK
NEOPLASMS
PATIENTS
SURVIVAL TIME
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BODY AREAS
COBALT ISOTOPES
DISEASES
ELECTROMAGNETIC RADIATION
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IONIZING RADIATIONS
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MEDICINE
MINUTES LIVING RADIOISOTOPES
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
RADIATIONS
RADIOISOTOPES
RADIOLOGY
THERAPY
YEARS LIVING RADIOISOTOPES
550603* - Medicine- External Radiation in Therapy- (1980-)